ImmuCell

ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ImmuCell (ICCC) reports stellar Q1 sales growth but faces margin challenges and regulatory delays

ImmuCell's Q1 2024 earnings call highlighted strong sales growth, operational achievements, margin challenges, and regulatory hurdles. The company aims to navigate these obstacles to drive future profitability and growth.

ImmuCell reports sales growth but struggles with margins and production

ImmuCell Corporation's Q2 2024 earnings call highlighted strong sales growth, challenges in gross margin improvement, and ongoing efforts to address production issues and regulatory processes. Despite improvements in EBITDA, the company faces financial constraints and operational hurdles that require strategic remediation.

ImmuCell reports robust sales growth and positive EBITDA in Q3

ImmuCell's Q3 2024 performance reflects strong sales growth, improved financial metrics, and a focus on innovation and partnerships.
While facing challenges in production and margin targets, the company is well-positioned to leverage opportunities for growth and profitability.
Overall, ImmuCell's strategic initiatives and financial progress signal a positive trajectory amidst operational challenges and regulatory processes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kits, and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter ended March 31, 2021.

ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2020 Results - Earnings Call Transcript

PORTLAND, Maine , Feb. 22, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced submission of a critical filing to the FDA related to Re-Tain™ and the Company's unaudited financial results for the year ended December 31, 2020.

ImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended December 31, 2020

Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020

PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a restructuring of its bank debt.

ImmuCell Announces Restructuring of its Bank Debt

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2020 Results - Earnings Call Transcript

Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2020

PORTLAND, Maine, Oct. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced preliminary, unaudited sales results for the third quarter ended September 30, 2020.

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2020 Results - Earnings Call Transcript

Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2020

PORTLAND, Maine, July  07, 2020  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced preliminary, unaudited sales results for the quarter ended June 30, 2020.

ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020

PORTLAND, Maine, June  16, 2020  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced receipt of a $500,000 subordinated loan from the Maine Technology Institute (MTI), whose mission is to support Maine’s innovation economy.

ImmuCell Receives $500,000 Loan from the Maine Technology

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2020 Results - Earnings Call Transcript

PORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced it will...

ImmuCell Corporation to Present at Lytham Partners Virtual Investor Conference

PORTLAND, Maine, April  02, 2020  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited product sales results for the first quarter ended March 31, 2020.

ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020

PORTLAND, Maine, March  11, 2020  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a complete refinancing of its bank debt.

ImmuCell Announces Refinancing of its Bank Debt

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2019 Results - Earnings Call Transcript

PORTLAND, Maine, Feb.  19, 2020  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a correction to its unaudited loss per share calculation for the fourth quarter ended December 31, 2019.

ImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019

PORTLAND, Maine, Jan.  21, 2020  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited product sales results for the year ended December 31, 2019.

ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2019 Results - Earnings Call Transcript

PORTLAND, Maine, Sept.  17, 2019  (GLOBE NEWSWIRE) --  ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a lease covering approximately 14,300 square feet of office and warehouse space effective approximately November 1, 2019.

ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

PORTLAND, Maine, Sept.  11, 2019  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a new agreement with Norbrook Laboratories, Limited of Newry, Northern Ireland covering the formulation and aseptic filling of its Nisin Drug Substance into syringes for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in dairy cows.

ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

Second Submission Anticipated Around Q3 2020

ImmuCell Receives FDA Response To First CMC Submission for Re-Tain™

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2019 Results - Earnings Call Transcript

ImmuCell Corporation's (ICCC) CEO Michael Brigham on Q1 2019 Results - Earnings Call Transcript

News for ImmuCell Stock (ICCC)